| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5254556 | JANSSEN PHARMS | 3-piperidinyl-1,2-benzisoxazoles |
Oct, 2013
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5352459 | JANSSEN PHARMS | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Dec, 2012
(11 years ago) | |
|
US5352459 (Pediatric) | JANSSEN PHARMS | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Jun, 2013
(10 years ago) | |
|
US5254556 (Pediatric) | JANSSEN PHARMS | 3-piperidinyl-1,2-benzisoxazoles |
Apr, 2014
(10 years ago) | |
| US6077843 | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May, 2017
(6 years ago) | |
|
US6077843 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov, 2017
(6 years ago) | |
| US6555544 | JANSSEN PHARMS | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
Nov, 2018
(5 years ago) | |
|
US6555544 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
May, 2019
(4 years ago) | |
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(6 years from now) | |
Invega Sustenna is owned by Janssen Pharms.
Invega Sustenna contains Paliperidone Palmitate.
Invega Sustenna has a total of 9 drug patents out of which 8 drug patents have expired.
Expired drug patents of Invega Sustenna are:
- US5352459
- US5352459*PED
- US5254556*PED
- US6077843
- US6077843*PED
- US6555544
- US6555544*PED
- US5254556
Invega Sustenna was authorised for market use on 31 July, 2009.
Invega Sustenna is available in suspension, extended release;intramuscular dosage forms.
Invega Sustenna can be used as dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s), treatment of schizophrenia.
Drug patent challenges can be filed against Invega Sustenna from 01 February, 2012.
The generics of Invega Sustenna are possible to be released after 26 January, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2011 |
| New Indication(I-698) | Nov 12, 2017 |
| M(M-215) | Dec 20, 2020 |
| New Dosage Form(NDF) | Jul 31, 2012 |
| Pediatric Exclusivity(PED) | Jan 31, 2013 |
| M(M-119) | Aug 29, 2015 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
NCE-1 date: 01 February, 2012
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loadin...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA family patents
